All In Biotech

Drug Trial Radar · NCT04544293

Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 164 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

164

Actual

Start

May 19, 2021

Primary completion

Nov 30, 2023

Study completion May 30, 2027

Sponsor

Lead sponsor
Savara Inc.Industry
Sponsor type
Industry
First posted
Sep 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim (MOL) or placebo (PBO) for 48 weeks. Subjects completing the 48-week placebo-controlled period will receive open-label treatment with once daily inhaled molgramostim for 96 weeks.

Conditions

  • Autoimmune Pulmonary Alveolar Proteinosis

Interventions

  • MolgramostimDrug

    Molgramostim 300 µg nebulizer solution

  • PlaceboDrug

    Matching placebo nebulizer solution

  • Molgramostim Open-labelDrug

    Molgramostim 300 µg nebulizer solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Percent (%) Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Adjusted for Hemoglobin Concentration to Week 24Time frame: From Baseline to Week 24

Locations

54 sites in 18 countries. Site status is shown where the registry gives one.

  • University Of Arkansas For Medical Services

    Little Rock, Arkansas

  • UCLA David Geffen School of Medicine

    Los Angeles, California

  • National Jewish Health

    Denver, Colorado

  • Yale University

    New Haven, Connecticut

  • University of Florida Health

    Gainesville, Florida

  • Emory University

    Atlanta, Georgia

  • Loyola University

    Maywood, Illinois

  • University of Maryland Medical Center

    Baltimore, Maryland

  • Washington University in St. Louis

    St Louis, Missouri

  • Duke University Medical Center

    Durham, North Carolina

  • Wake Med Health & Hospital

    Raleigh, North Carolina

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • University of Pennsylvania Perelman School of Medicine - Pulmonology

    Philadelphia, Pennsylvania

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • UT Southwestern Medical Center

    Dallas, Texas

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Hôpital Erasme

    Brussels, Brussels Capital, Belgium

  • UZ Leuven - Campus Gasthuisberg - Pneumologie

    Leuven, Vlaams Brabant, Belgium

  • University of Calgary

    Calgary, Alberta, Canada

  • St Joseph's Healthcare Hamilton Research

    Hamilton, Ontario, Canada

  • University Institute of Cardiology and Respirology of Quebec

    Québec, Quebec, Canada

  • Hôpital Louis Pradel

    Bron, Auvergne-Rhône-Alpes, France

  • CHU Pontchaillou

    Rennes, Brittany Region, France

  • Thoraxklinik Heidelberg gGmbH am Universitätsklinikum Heidelberg

    Heidelberg, Baden-Wurttemberg, Germany

  • Asklepios Fachkliniken Muenchen-Gauting

    Muenchen-Gauting, Bavaria, Germany

  • Ruhrlandklinik Westdeutsches Lungenzentrum

    Essen, North Rhine-Westphalia, Germany

  • Attikon University Hospital

    Athens, Greece

  • St. Vincent's University Hospital

    Dublin, Ireland

  • Fondazione IRCCS Policlinico San Matteo

    Pavia, Lombardy, Italy

  • Aichi Medical University Hospital

    Nagakute, Japan

  • Chiba University Hospital - Respiratory Medicine

    Chiba, Chiba, Japan

  • Hokkaido University Hospital

    Sapporo, Hokkaidô, Japan

  • Kanagawa Cardiovascular and Respiratory Center

    Yokohama, Kanagawa, Japan

  • Kumamoto University Hospital

    Kumamoto, Kumamoto, Japan

  • Tohoku University Hospital - Respiratory Tract Medicine

    Sendai, Miyagi, Japan

  • National Hospital Organization Kinki-Chuo Chest medical Center

    Sakai, Osaka, Japan

  • Saitama Red Cross Hospital

    Saitama, Saitama, Japan

  • Kyorin University Hospital

    Mitaka, Tokyo, Japan

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.